BXNDA — BLS Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- AU$211.42m
- AU$209.18m
- AU$29.29m
Australia's Bioxyne rises to near 8-year high after company secures German supply deal
Australia's Bioxyne at two-week high on supply deal with Remidose LATAM
Brief: Bioxyne Expands LATAM Footprint First Supply Agreement Costa Rica
Australia's Bioxyne hits nearly 8-year high on cannabis firm deal
Brief: Bioxyne Signs Manufacturing Agreement With Global Cannabis Leader, Aurora Cannabis
Australia's Bioxyne hits five-month high on commercialising psilocybin capsules
Brief: Bioxyne Commercialises GMP-Manufactured Psilocybin Capsules
Brief: Bioxyne Reports Qtrly Revenue A$17.2 Mln
Brief: Bioxyne's Unit Enters Manufacturing Agreement With Remidose Latam Srl
Brief: Bioxyne Executed Exclusive Import, Manufacture And Supply Agreement With Curaleaf International For Australia
Brief: Bioxyne Reports Record Quarterly Revenue Of A$14.1 Million
Brief: Bioxyne Announces Dual Listing On Frankfurt Stock Exchange
Brief: Bioxyne Ltd's Unit Well Positioned To Capitalise On Easing Regulations On U.S. Cannabis Classification
Brief: Bioxyne Ltd Received Import Authorisations Medical Cannabis Products
Brief: Bioxyne Reports Full Year FY2026 Revenue Guidance Of A$65 Million - A$75 Million
Brief: Bioxyne Filed Summons Against Major Shareholder
Australia's Bioxyne jumps on strong quarterly results, upbeat outlook
Brief: Bioxyne Says FY25 Unaudited Revenue Of A$29.3 Million
Australia's Bioxyne jumps on entering German market with $3.7 mln deal